Jerry L Nadler Selected Research

lisofylline

5/2012	Amelioration of type 1 diabetes following treatment of non-obese diabetic mice with INGAP and lisofylline.
7/2006	Synthesis and biological evaluation of lisofylline (LSF) analogs as a potential treatment for Type 1 diabetes.
6/2006	Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes.
1/2005	Lisofylline: a potential lead for the treatment of diabetes.
12/2003	Lisofylline, a novel antiinflammatory compound, protects mesangial cells from hyperglycemia- and angiotensin II-mediated extracellular matrix deposition.
11/2003	Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jerry L Nadler Research Topics

Disease

30	Inflammation (Inflammations) 01/2022 - 05/2003
21	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 06/2002
16	Insulin Resistance 01/2018 - 05/2002
14	Atherosclerosis 11/2017 - 09/2003
12	Obesity 10/2014 - 10/2007
11	Type 2 Diabetes Mellitus (MODY) 01/2017 - 05/2002
10	Hyperglycemia 11/2016 - 12/2003
4	Glucose Intolerance 01/2016 - 03/2004
4	Peripheral Nervous System Diseases (PNS Diseases) 08/2013 - 09/2010
3	Infections 02/2020 - 01/2005
3	Diabetic Neuropathies (Diabetic Neuropathy) 08/2013 - 09/2010
3	Diabetic Nephropathies (Diabetic Nephropathy) 06/2007 - 12/2003
2	Thrombosis (Thrombus) 01/2021 - 07/2017
2	Body Weight (Weight, Body) 03/2016 - 03/2004
2	Acute Lung Injury 09/2012 - 10/2009
2	Pneumonia (Pneumonitis) 09/2012 - 10/2009
2	Disease Progression 03/2011 - 04/2003
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2011 - 01/2006
2	Cardiovascular Diseases (Cardiovascular Disease) 12/2010 - 10/2002
2	Diabetic Angiopathies (Diabetic Angiopathy) 09/2004 - 09/2003
2	Hypertrophy 11/2002 - 03/2002
1	Metabolic Diseases (Metabolic Disease) 11/2021
1	Vascular System Injuries 07/2017
1	Wounds and Injuries (Trauma) 01/2017
1	Autoimmune Diseases (Autoimmune Disease) 01/2015
1	Edema (Dropsy) 09/2012
1	Hyperinsulinism (Hyperinsulinemia) 02/2012
1	Chronic Disease (Chronic Diseases) 07/2011
1	Atrophy 09/2010

Drug/Important Bio-Agent (IBA)

25	Arachidonate 15-Lipoxygenase (Arachidonate 15 Lipoxygenase)IBA 01/2022 - 03/2004
19	Insulin (Novolin)FDA Link 01/2022 - 06/2002
14	Glucose (Dextrose)FDA LinkGeneric 11/2017 - 12/2003
13	CytokinesIBA 02/2020 - 06/2002
8	EnzymesIBA 11/2021 - 03/2007
8	Arachidonate 12-Lipoxygenase (12 Lipoxygenase)IBA 01/2021 - 03/2002
6	AcidsIBA 07/2017 - 03/2002
6	lisofyllineIBA 05/2012 - 11/2003
5	Proteins (Proteins, Gene)FDA Link 10/2017 - 03/2002
5	LipidsIBA 07/2017 - 03/2002
4	Arachidonic Acid (Vitamin F)IBA 09/2010 - 03/2002
3	Biological ProductsIBA 01/2017 - 07/2006
3	Apolipoproteins E (ApoE)IBA 11/2015 - 10/2004
3	Interleukin-12 (IL 12)IBA 01/2015 - 05/2004
3	Sorbitol (Yal)FDA Link 04/2012 - 10/2007
3	ApolipoproteinsIBA 02/2012 - 10/2004
3	LipoxygenasesIBA 01/2011 - 05/2008
3	Streptozocin (Streptozotocin)FDA Link 06/2010 - 05/2003
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2007 - 09/2003
2	EicosanoidsIBA 01/2021 - 01/2014
2	Interferon Type IIBA 02/2020 - 10/2017
2	NF-kappa B (NF-kB)IBA 02/2020 - 05/2008
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 05/2006
2	Blood Glucose (Blood Sugar)IBA 11/2016 - 09/2010
2	Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)IBA 03/2016 - 03/2002
2	Mitogen-Activated Protein KinasesIBA 08/2013 - 04/2012
2	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 05/2012 - 07/2006
2	Aldehyde Reductase (Aldose Reductase)IBA 04/2012 - 10/2007
2	p38 Mitogen-Activated Protein KinasesIBA 07/2011 - 03/2002
2	Fingolimod Hydrochloride (FTY720)FDA Link 03/2011 - 04/2003
2	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA 01/2011 - 05/2008
2	Messenger RNA (mRNA)IBA 06/2010 - 05/2006
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2006 - 09/2004
2	Oxidants (Oxidizing Agents)IBA 01/2006 - 09/2003
2	Angiotensin IIIBA 12/2003 - 03/2002
2	Fibronectins (Fibronectin)IBA 11/2002 - 03/2002
1	ML355IBA 01/2021
1	Viral ProteinsIBA 02/2020
1	Antiviral Agents (Antivirals)IBA 10/2017
1	Phospholipids (Phosphatides)FDA LinkGeneric 07/2017
1	Thrombin FDA Link 07/2017
1	Phosphatidylethanolamines (Cephalins)IBA 07/2017
1	AnaphylatoxinsIBA 01/2017
1	Complement C1 (Complement 1)IBA 01/2017
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2017
1	CCR2 ReceptorsIBA 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	InterferonsIBA 01/2017
1	Glucagon (Glukagon)FDA Link 03/2016
1	Glucagon-Like Peptide 1 (GLP 1)IBA 03/2016
1	6alpha-ethyl-23(S)-methylcholic acidIBA 03/2016
1	Letrozole (Femara)FDA LinkGeneric 01/2016
1	Estrogens (Estrogen)FDA Link 01/2016
1	Estradiol (Delestrogen)FDA LinkGeneric 01/2016
1	AutoantibodiesIBA 01/2015
1	Lipoxygenase InhibitorsIBA 08/2013
1	LipopolysaccharidesIBA 09/2012
1	Peptide FragmentsIBA 05/2012
1	INGAP peptideIBA 05/2012
1	Insulin ReceptorIBA 02/2012
1	Insulin Receptor Substrate ProteinsIBA 02/2012
1	Drug CombinationsIBA 07/2011
1	baicaleinIBA 07/2011
1	FlavonoidsIBA 07/2011
1	Pharmaceutical PreparationsIBA 07/2011
1	Reducing AgentsIBA 01/2011
1	Protein Isoforms (Isoforms)IBA 12/2010

Therapy/Procedure

4	Therapeutics 06/2015 - 12/2007
2	Islets of Langerhans Transplantation 01/2005 - 01/2004
1	Lasers (Laser) 01/2017
1	Bariatric Surgery 08/2014